AAP
TBPH icon

Arax Advisory Partners’s Theravance Biopharma TBPH Stock Holding History

Arax Advisory Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Buy
+604
New +$10K ﹤0.01% 4323
2026
Q1 		– Sell
-6
Closed -$112 – 4307
2025
Q4 		$112 Sell
6
-220
-97% -$3.65K ﹤0.01% 3809
2025
Q3 		$3.3K Buy
+226
New +$2.86K ﹤0.01% 2989
2024
Q4 		– Sell
-57
Closed -$460 – 2739
2024
Q3 		$460 Hold
57
– – ﹤0.01% 2411
2024
Q2 		$484 Buy
+57
New +$514 ﹤0.01% 2336

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Arax Advisory Partners's TBPH Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 604 shares worth $10.3K. The stake represents ﹤0.01% of the portfolio and ranks #4323 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in TBPH as recently as Q4 2025.

Arax Advisory Partners first reported a position in TBPH in Q2 2024 and has held it in 5 quarters since. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Arax Advisory Partners held 604 shares of Theravance Biopharma worth $10.3K as of Q2 2026.
  • Theravance Biopharma was a new Arax Advisory Partners position in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4323 holding.
  • Arax Advisory Partners first reported a position in Theravance Biopharma in Q2 2024 and has held it in 5 quarters since.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.